ALPCO, a Salem, N.H.-based distributor of immunoassay-based diagnostics and a member of the NuvinkaDx portfolio, has received Health Canada licenses for H. pylori Stool Antigen and Lactoferrin stool assays, adding both tests to the KleeYa® automated GI testing platform.
The expansion matters to the functional nutrition and gut-health sector because lactoferrin—an iron-binding glycoprotein found naturally in colostrum and increasingly used as a nutraceutical ingredient—is a recognized biomarker of intestinal inflammation. Measuring fecal lactoferrin levels is a validated clinical endpoint for distinguishing inflammatory bowel conditions from non-inflammatory gastrointestinal disorders, giving clinicians and integrative-health practitioners a quantitative tool to guide dietary and supplement protocols. H. pylori antigen detection in stool, meanwhile, is a frontline method for confirming active infection and monitoring eradication, directly relevant to practitioners working with patients on probiotic and gut-health regimens.
Why Lactoferrin Matters
Lactoferrin has moved well beyond its diagnostic role. Ingredient suppliers now offer standardized lactoferrin fractions as finished-formulation inputs for immune-support and gut-integrity supplements, and consumer demand for science-backed gut-health products continues to outpace most functional food categories. Having a licensed, automated assay available in Canada gives formulators, clinical researchers, and integrative practitioners a regulatory-grade measurement tool to anchor biomarker-driven product development and substantiate structure-function claims with objective data.
Platform and Market Context
KleeYa® is positioned as a compact, automated immunoassay analyzer designed for high-throughput stool testing in clinical laboratory settings. Adding Health Canada-licensed menu items directly expands the platform's commercial reach into Canada's regulated diagnostic market. For the broader functional foods and nutraceutical supply chain, the availability of licensed GI biomarker assays in Canada supports growing operator interest in clinically validated gut-health positioning—a segment that research firms consistently rank among the fastest-growing areas of the global nutraceutical market. Brands and contract manufacturers pursuing evidence-based formulation increasingly rely on biomarker endpoints like fecal lactoferrin and H. pylori status to design and validate intervention studies. ALPCO's expanded Canadian menu lowers the barrier to running those studies with regulatory-recognized methodology.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
